140 related articles for article (PubMed ID: 31579332)
1. Tegafur and 5-fluorouracil levels in tears and changes in tear volume in long-term users of the oral anticancer drug S-1.
Kuriki R; Hata T; Nakayama K; Ito Y; Misawa K; Ito S; Tatematsu M; Kaneda N
Nagoya J Med Sci; 2019 Aug; 81(3):415-425. PubMed ID: 31579332
[TBL] [Abstract][Full Text] [Related]
2. Determination of 5-fluorouracil and tegafur in tear fluid of patients treated with oral fluoropyrimidine anticancer agent, S-1.
Akune Y; Yamada M; Shigeyasu C
Jpn J Ophthalmol; 2018 Jul; 62(4):432-437. PubMed ID: 29931401
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of S-1 monotherapy in plasma and in tears for gastric cancer patients.
Yasui H; Kawakami T; Kashiwagi H; Mori K; Omae K; Kasai J; Yoshisue K; Kawahira M; Tsushima T; Machida N; Fukutomi A; Yamaguchi K
Int J Clin Oncol; 2019 Jun; 24(6):660-665. PubMed ID: 31011915
[TBL] [Abstract][Full Text] [Related]
4. Changes in tear volume and ocular symptoms of patients receiving oral anticancer drug S-1.
Kuriki R; Hata T; Nakayama K; Ito Y; Misawa K; Ito S; Tatematsu M; Kaneda N
J Pharm Health Care Sci; 2018; 4():3. PubMed ID: 29445512
[TBL] [Abstract][Full Text] [Related]
5. Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
Yoshisue K; Kanie S; Nishimura T; Chikamoto J; Nagayama S
J Pharm Pharmacol; 2009 Dec; 61(12):1643-51. PubMed ID: 19958587
[TBL] [Abstract][Full Text] [Related]
6. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
Schöffski P
Anticancer Drugs; 2004 Feb; 15(2):85-106. PubMed ID: 15075664
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients.
Lee HW; Seong SJ; Kang WY; Ohk B; Gwon MR; Kim BK; Cho S; Cho K; Sung YK; Yoon YR; Kim JG
Drug Des Devel Ther; 2019; 13():3127-3136. PubMed ID: 31564829
[TBL] [Abstract][Full Text] [Related]
8. Determination of tegafur, 5-fluorouracil, gimeracil and oxonic acid in human plasma using liquid chromatography-tandem mass spectrometry.
Liu K; Zhong D; Zou H; Chen X
J Pharm Biomed Anal; 2010 Aug; 52(4):550-6. PubMed ID: 20138454
[TBL] [Abstract][Full Text] [Related]
9. Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy.
Kim WY; Nakata B; Hirakawa K
Cancer Sci; 2007 Oct; 98(10):1604-8. PubMed ID: 17683513
[TBL] [Abstract][Full Text] [Related]
10. High-throughput method to analyze tegafur and 5-fluorouracil in human tears and plasma using hydrophilic interaction liquid chromatography/tandem mass spectrometry.
Shiokawa R; Lee XP; Yamada M; Fujishiro M; Sakamaki H; Hasegawa C; Ishida H; Ikeda K; Fujita KI; Iwabuchi S; Onda H; Kumazawa T; Sasaki Y; Sato K; Matsuyama T
Rapid Commun Mass Spectrom; 2019 Dec; 33(24):1906-1914. PubMed ID: 31323696
[TBL] [Abstract][Full Text] [Related]
11. Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling.
Kim TH; Shin S; Shin JC; Bulitta JB; Weon KY; Yoo SD; Park GY; Jeong SW; Kwon DR; Min BS; Woo MH; Shin BS
Molecules; 2017 Sep; 22(9):. PubMed ID: 28880240
[TBL] [Abstract][Full Text] [Related]
12. A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil.
Saif MW; Rosen LS; Saito K; Zergebel C; Ravage-Mass L; Mendelson DS
Anticancer Res; 2011 Feb; 31(2):625-32. PubMed ID: 21378348
[TBL] [Abstract][Full Text] [Related]
13. Excessive watering eyes in gastric cancer patients receiving S-1 chemotherapy.
Tabuse H; Kashiwagi H; Hamauchi S; Tsushima T; Todaka A; Yokota T; Machida N; Yamazaki K; Fukutomi A; Onozawa Y; Mori K; Boku N; Ichinose M; Yasui H
Gastric Cancer; 2016 Jul; 19(3):894-901. PubMed ID: 26362271
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Tominaga K; Higuchi K; Okazaki H; Suto R; Hamaguchi M; Tanigawa T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Oshitani N; Matsumoto T; Arakawa T
Oncology; 2004; 66(5):358-64. PubMed ID: 15331922
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients.
Comets E; Ikeda K; Hoff P; Fumoleau P; Wanders J; Tanigawara Y
J Pharmacokinet Pharmacodyn; 2003 Aug; 30(4):257-83. PubMed ID: 14650374
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
17. S-1-Induced Lacrimal Drainage Obstruction and Its Association with Ingredients/Metabolites of S-1 in Tears and Plasma: A Prospective Multi-institutional Study.
Kim N; Kim JW; Baek JH; Kim JS; Choung HK; Kim TY; Lee KH; Bang YJ; Khwarg SI; Ahn SH; Park DJ; Kim HH; Chung JY; Ahn S; Lee KW
Cancer Res Treat; 2018 Jan; 50(1):30-39. PubMed ID: 28253565
[TBL] [Abstract][Full Text] [Related]
18. Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1.
Tsuruoka Y; Kamano T; Kitajima M; Kawai K; Watabe S; Ochiai T; Sakamoto K; Shirasaka T
Anticancer Drugs; 2006 Apr; 17(4):393-9. PubMed ID: 16549996
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacokinetics of S-1].
Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
[TBL] [Abstract][Full Text] [Related]
20. Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin.
Peer CJ; McManus TJ; Hurwitz HI; Petros WP
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Jun; 898():32-7. PubMed ID: 22565063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
